Metformin Hydrochloride Patent Expiration
Metformin Hydrochloride was first introduced by Emd Serono Inc
Metformin Hydrochloride Patents
Given below is the list of patents protecting Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Riomet Er | US9962336 | Extended release suspension compositions | May 01, 2035 | Sun Pharm |
| Glumetza | US7780987 | Controlled release dosage forms |
Mar 23, 2025
(Expired) | Santarus Inc |
| Glumetza | US8323692 | Controlled release dosage forms |
Mar 23, 2025
(Expired) | Santarus Inc |
| Riomet | US6890957 | Liquid formulation of metformin |
Sep 14, 2023
(Expired) | Ranbaxy |
| Glumetza | US6723340 | Optimal polymer mixtures for gastric retentive tablets |
Oct 25, 2021
(Expired) | Santarus Inc |
| Fortamet | US6790459 | Methods for treating diabetes via administration of controlled release metformin |
Mar 17, 2021
(Expired) | Andrx Labs Llc |
| Fortamet | US6866866 | Controlled release metformin compositions |
Mar 17, 2021
(Expired) | Andrx Labs Llc |
| Glumetza | US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun 20, 2020
(Expired) | Santarus Inc |
| Fortamet | US6099859 | Controlled release oral tablet having a unitary core |
Mar 20, 2018
(Expired) | Andrx Labs Llc |
| Fortamet | US6495162 | Controlled release oral tablet having a unitary core |
Mar 20, 2018
(Expired) | Andrx Labs Llc |
| Fortamet | US7919116 | Controlled release metformin formulations |
Mar 20, 2018
(Expired) | Andrx Labs Llc |
| Fortamet | US8475841 | Controlled release metformin formulations |
Mar 20, 2018
(Expired) | Andrx Labs Llc |
| Glucophage Xr | US6475521 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar 19, 2018
(Expired) | Emd Serono Inc |
| Glucophage Xr | US6660300 | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar 19, 2018
(Expired) | Emd Serono Inc |
| Glumetza | US6340475 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Santarus Inc |
| Glumetza | US6635280 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Santarus Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Metformin Hydrochloride's patents.
Latest Legal Activities on Metformin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Metformin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Nov, 2021 | US9962336 |
| Email Notification Critical
| 21 Jan, 2021 | US9962336 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 21 Jan, 2021 | US9962336 |
| Correspondence Address Change Critical
| 19 Jan, 2021 | US9962336 |
| Correspondence Address Change Critical
| 20 Jul, 2020 | US9962336 |
| Recordation of Patent Grant Mailed Critical
| 08 May, 2018 | US9962336 |
| Patent Issue Date Used in PTA Calculation Critical
| 08 May, 2018 | US9962336 |
| Email Notification Critical
| 19 Apr, 2018 | US9962336 |
| Issue Notification Mailed Critical
| 18 Apr, 2018 | US9962336 |
| Application Is Considered Ready for Issue Critical
| 30 Mar, 2018 | US9962336 |
Metformin Hydrochloride's Family Patents
